Octreotide LAR treatment throughout pregnancy in an acromegalic woman

M Fassnacht, B Capeller, W Arlt, T Steck, B Allolio

Research output: Contribution to journalArticlepeer-review

67 Citations (Scopus)


We report a 24-year-old woman with active acromegaly despite pituitary surgery and irradiation who received continuous octreotide LAR treatment for the control of GH excess throughout her pregnancy. The patient delivered a healthy girl following an uneventful pregnancy. Despite a substantial materno-fetal transfer of octreotide, postnatal development was normal with length parameters around the 50th percentile at 3 months of age. In almost all previously described cases (n = 13) octreotide was stopped after the diagnosis of pregnancy was established. No side-effects of mother or fetus have been reported. Octreotide treatment in pregnancy seems to be feasible and safe. Due to the still-limited number of reported cases, the potential benefits of octreotide treatment should be weighed carefully against its possible risks.

Original languageEnglish
Pages (from-to)411-5
Number of pages5
JournalClinical Endocrinology
Issue number3
Publication statusPublished - Sept 2001


  • Acromegaly
  • Adenoma
  • Adult
  • Antineoplastic Agents, Hormonal
  • Delayed-Action Preparations
  • Female
  • Humans
  • Maternal-Fetal Exchange
  • Octreotide
  • Pituitary Neoplasms
  • Pregnancy
  • Pregnancy Complications, Neoplastic
  • Pregnancy Outcome
  • Prenatal Care


Dive into the research topics of 'Octreotide LAR treatment throughout pregnancy in an acromegalic woman'. Together they form a unique fingerprint.

Cite this